In Focus: Minimal Residual Disease in multiple myeloma
Important information
The following feature is intended for healthcare professionals only. Please tick the box below to confirm that you are a healthcare professional.
FEATURES
MRD negativity as a goal of therapy for multiple myeloma: an interview with Rafael Alonso
Dr Rafael Alonso (Hospital Universitario 12 de Octubre, Madrid, Spain) discusses MRD negativity as a measure of depth of response in multiple myeloma. Dr Alonso also highlights how critical MRD negativity is for patients receiving frontline treatment, as well as his personal experience with MRD testing. View the video here >>>.
Minimal Residual Disease in multiple myeloma infographic
MRD is the low level of malignant cells that persist in the bone marrow after treatment but cannot be detected by conventional outcomes measures and which eventually lead to relapse. This infographic provides a visual snapshot of the importance of MRD in multiple myeloma. View the infographic here >>>.
The opinions expressed in the above content pieces are of the contributor’s own and do not necessarily reflect the views of Oncology Central or Future Science Group.
Sponsored and funded by:
MAT-GLB-2300223 (1.0) 01/23